---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124436"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:01:43.838661+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences reports Q3 2024 net loss of $8.7M; cash runway through end of 2025; topline data expected Dec 2024

## Summary
- Net loss of $8.7M in Q3 2024 ($29.5M nine months); cash and equivalents $60.1M as of Sept 30, 2024.
- R&D expenses fell to $6.6M (Q3 2024) from $13.5M (Q3 2023) due to study terminations and completions.
- Collaboration revenue of $0.6M in Q3 2024 vs $3.1M a year ago, from Kaken Pharmaceutical partnership.
- Topline results from CAHmelia-204 (adult CAH) and CAHptain-205 (adult & pediatric CAH) trials expected December 2024.
- End-of-Phase 2 meeting with FDA for tildacerfont anticipated in first half of 2025.

## SEC filing metadata
- accession: 0000950170-24-124436
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017024124436/0000950170-24-124436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017024124436/sprb-20241111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124436
- JSON: https://secwatch.observer/filing/0000950170-24-124436.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124436.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.